Arca Biopharma files application for Covid-19 drug treatment

Westminster-based biotech company Arca Biopharma has submitted an Investigational New Drug application for Covid-19. The application was filed under the Coronavirus Treatment Acceleration Program. The application will evaluate the use of one of Arca Biopharma's drugs, AB201, as a treatment for patients hospitalized with Covid-19. The 13-employee Arca Biopharma typically focuses on genetically targeted therapie s for cardiovascular diseases. AB201 is believed to be effective with RNA viruses, which…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news